Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Amid rising cancer burden in India, the mRNA custom-made cancer vaccine for melanoma has intriguing potential. ​While typical ...

Earlier this week, biotechnology company Amplitude Therapeutics announced a partnership with global pharmaceutical ...

President Donald Trump’s announcement this week of White House aide Heidi Overton as his pick to lead the FDA gave the pharma ...

The Trump administration is reportedly ending $500 million in funding for mRNA vaccine development, with claims that natural ...

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug ...

For years, Moderna, Inc‘s MRNA biggest challenge wasn’t developing new medicines — it was convincing investors that it could ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

The Centers for Disease Control and Prevention has brought on a communications and public affairs official who appears to ...

Early results from final-stage trial of individualised melanoma jab offer hope of more tailor-made cancer treatments ...

The COVID-19 summer surge is back, but at much lower rates than before, according to state health data. The Centers for ...

Moderna and Merck's personalised cancer vaccine succeeds in a Phase 3 trial, raising hopes for a new generation of cancer ...